

Please type a plus sign (+) inside this box →

+

PTO/SB/08B (6-95)  
Approved for use through 07/31/96, OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

1449B/PTO Rev. 10/95		U.S. Department of Commerce Patent and Trademark Office		<b>Complete if Known</b>	
<b>LIST OF PRIOR ART CITED BY APPLICANT</b> (use as many sheets as necessary)				Application Number	10/553,291
				Filing Date	October 14, 2005
				First Named Inventor	Mary J. EATON
				Group Art Unit	1647
				Examiner Name	
Sheet	5	of	6	Attorney Docket Number	US 1442/05 (VA)

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book), magazine, journal, serial, symposium, catalog, etc., date, page(s), volume-issue number(s), Publisher, country, where published, source.	T <sup>2</sup>
		Bennett GJ and Xie Y-K. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 1988;33: 87-107.	
		Kim SH and Chung JM. An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain 1992;50: 355-363.	
		Yeziarski RP, Liu S, Ruenes GL, Kajander KJ. Behavioral and pathological characteristics of a central pain model following spinal injury. VIIIth World Congress on Pain 1996; <u>IASP PRESS, p. 379.</u>	
		Yeziarski RP and Park SH. The mechanosensitivity of spinal sensory neurons following intraspinal injections of quisqualic acid in the rat. Neurosci Lett 1998;157: 115-119.	
		Smart D, Hirst RA, Hirota K, Grandy DK, Lambert DG. The effects of recombinant rat mu-opioid receptor activation in CHO cells on phospholipase C, [Ca <sup>2+</sup> ] <sub>i</sub> and adenylyl cyclase. Br J Pharmacol 1997; 120: 1165-1171.	
		Schumm MA, Castellanos DA, Frydel BL, Sagen J. Direct cell-cell contact required for neurotrophic effect of chromaffin cells on neural progenitor cells. Brain Res., 146 (1-2):1-13.(2003).	
		Schumm MA, Castellanos DA, Frydel BR, Sagen J. Enhanced viability and neuronal differentiation of neural progenitors by chromaffin cell co-culture. Brain Res., 137(2):115-25(2002).	
		Schumm MA, Castellanos DA, Frydel BR, Sagen J. Improved neural progenitor cell survival when co-grafted with chromaffin cells in the rat striatum. Exp Neurol., 185(1):133-42 (2004).	
		Hama AT, Siegan JB, Herzberg U, Sagen J. 1. NMDA-induced spinal hypersensitivity is reduced by naturally derived peptide analog [Ser <sup>1</sup> ]histogranin. Pharmacol Biochem Behav. 62(1):67-74 (1999).	
		Siegan JB, Hama AT, Sagen J. Suppression of neuropathic pain by a naturally-derived peptide with NMDA antagonist activity. Brain Res., 755(2):331-4 (1997).	

Examiner Signature	/Daniel Gamett/ (12/14/2007)	Date Considered	
--------------------	------------------------------	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.


Burden Hour Statement: This form is estimated to take .2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DG/

AE  
12-16  
68

+

+



Application Number	10/553,291
Filing Date	October 14, 2005
First Named Inventor	Mary J. EATON
Group Art Unit	1647
Examiner Name	GAMETT, Daniel C.
Attorney Docket Number	US 1442/05 (VA)

**Attorney Docket Number** | **US 1442/05 (VA)**

[illegible][illegible]

Date Considered

**Burden Hour Statement:** This form is estimated to take .2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. ~~DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:~~ Assistant Commissioner for Patents, Washington, DC 20231.

ALL INFORMATION CONTAINED HEREIN IS UNCLASSIFIED EXCEPT WHERE SHOWN OTHERWISE